Anthracycline doses in patients with liver dysfunction: do UK oncologists follow current recommendations?
1998

Anthracycline Doses in Patients with Liver Dysfunction

Sample size: 173 publication Evidence: moderate

Author Information

Author(s): NA Dobbs, CJ Twelves

Primary Institution: Imperial Cancer Research Fund Medical Oncology Unit

Hypothesis

Do UK oncologists follow current recommendations for anthracycline dose modifications in patients with liver dysfunction?

Conclusion

UK oncologists show significant variability in prescribing anthracycline doses for patients with liver dysfunction, often differing from current recommendations.

Supporting Evidence

  • Oncologists reported a wide range of anthracycline doses prescribed for patients with liver dysfunction.
  • Medical oncologists were more likely to prescribe lower doses than clinical oncologists.
  • 42% of oncologists would prescribe a dose at least 25% greater than the recommended dose for patients with raised bilirubin.

Takeaway

Doctors sometimes give different amounts of medicine to cancer patients with liver problems, and they don't always follow the rules about how much to give.

Methodology

A postal questionnaire was sent to UK consultant oncologists asking about their prescribing habits for anthracyclines in patients with liver dysfunction.

Potential Biases

Potential bias due to the self-selection of respondents and the nature of postal surveys.

Limitations

The study relies on self-reported data from oncologists, which may not fully represent actual prescribing practices.

Participant Demographics

UK consultant oncologists, including both clinical and medical oncologists.

Statistical Information

P-Value

0.04

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication